Abstract：Objective To investigate the expression of serum microRNA-374b-5p (miR-374b-5p) and vascular endothelial growth factor-C (VEGF-C) in patients with non-small cell lung cancer (NSCLC) and the relationship with prognosis. Methods A total of 105 patients with NSCLC admitted to Linyi Cancer Hospital of Shandong Province (hereinafter referred to as “our hospital”) from February 2018 to September 2019 were selected as NSCLC group, and 54 healthy individuals with physical examination during the same period in our hospital were control group. Serum miR-374b-5p and VEGF-C expression between two groups were detected and compared; the relationship between miR-374b-5p and VEGF-C was predicted by TargetScan database; the correlation between serum miR-374b-5p and VEGF-C expression was analyzed by Pearson correlation coefficient; the survival curves of NSCLC patients with different expression of miR-374b-5p and VEGF-C were plotted by K-M method; the influencing factors of NSCLC death were analyzed by Cox regression. Results Serum miR-374b-5p expression in NSCLC group was lower than that in control group, and VEGF-C expression was higher than that in control group, with statistical significance (P＜0.05). MiR-374b-5p and VEGF-C had binding sites in the 3’-untranslated regions of 381-388 and 585-591. Serum miR-374b-5p was negatively correlated with VEGF-C expression in NSCLC patients (r=-0.735, P＜0.01). The expression of serum miR-374b-5p and VEGF-C of NSCLC patients with different differentiation degrees, TNM stages, and lymph node metastasis were statistically significant (P＜0.05). The survival curves of NSCLC patients with different expression of miR-374b-5p and VEGF-C were significantly different (P＜0.05). TNM stage Ⅲ, lymph node metastasis, and increased VEGF-C were independent risk factors for NSCLC death (HR=3.195, 4.212, 1.102, P＜0.05), and miR-374b-5p was independent protective factor (HR=0.988, P＜0.05). Conclusion The expression of miR-374b-5p is low and expression of VEGF-C is high in serum of NSCLC patients, and it is related to differentiation degree, TNM stage, lymph node metastasis, and prognosis.
李敏婕1 刘淑红2 陈洪云1 余海青1. 非小细胞肺癌患者血清miR-374b-5p、VEGF-C的表达及与预后的关系[J]. 中国医药导报, 2023, 20(26): 22-26.
LI Minjie1 LIU Shuhong2 CHEN Hongyun1 YU Haiqing1. Expression of serum miR-374b-5p and VEGF-C in patients with non-small cell lung cancer and the relationship with prognosis. 中国医药导报, 2023, 20(26): 22-26.
[1] Sung H，Ferlay J，Siegel RL，et al. Global Cancer Statistics 2020：GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries [J]. CA Cancer J Clin，2021，71（3）：209-249.
[2] 中华医学会肿瘤学分会，中华医学会杂志社.中华医学会肺癌临床诊疗指南（2022版）[J].中华肿瘤杂志，2022， 44（6）：457-490.
[3] 中国临床肿瘤学会血管靶向治疗专家委员会，中国临床肿瘤学会非小细胞肺癌专家委员会，中国临床肿瘤学会非小细胞肺癌抗血管生成药物治疗专家组.晚期非小细胞肺癌抗血管生成药物治疗中国专家共识（2020版）[J].中华肿瘤杂志，2020，42（12）：1063-1077.
[4] 方庆亮，顾小强，毛广敏，等.miR-539对非小细胞肺癌细胞增殖凋亡的影响及机制[J].临床肿瘤学杂志，2022， 27（6）：540-543.
[5] 李长生，张莞萍，任中海.circ-SFMBT2通过靶向miR-7- 5p/ ADAM10轴对非小细胞肺癌细胞生物学行为的影响[J].中华医学遗传学杂志，2022，39（2）：162-170.
[6] Wu ZZ，Xu Q. Bladder cancer-associated transcript 1 promotes melanoma cell proliferation and invasion via the miR- 374b-5p/U2-associated factor homology motif kinase 1 axis [J]. Kaohsiung J Med Sci，2022，38（2）：97-107.
[7] 李霞，任玉嫄，林洁，等.miR-374b-5p靶向调控ING1表达及对乳腺癌细胞增殖、侵袭和转移的影响[J].解放军医药杂志，2020，32（2）：26-31.
[8] Wautier JL，Wautier MP. Vascular Permeability in Diseases [J]. Int J Mol Sci，2022，23（7）：3645.
[9] Wang CA，Tsai SJ. The non-canonical role of vascular endothelial growth factor-C axis in cancer progression [J]. Exp Biol Med（Maywood），2015，240（6）：718-724.
[10] 陈旭轮，王帅，宋明欣，等.过表达环状RNA circTCF25经miR-128靶向VEGF-C对膀胱癌细胞生物学行为的影响[J].中国实验诊断学，2022，26（1）：77-80.
[11] 杨雯迪，李亚军.miR-203a-3p靶向调控VEGF-C表达对卵巢癌恶性生物学特征的影响[J].中国妇幼健康研究，2022，33（1）：66-72.
[12] 中国抗癌协会肺癌专业委员会，中华医学会肿瘤学分会肺癌学组，中国胸部肿瘤研究协作组.Ⅰ~ⅢB期非小细胞肺癌完全切除术后辅助治疗指南（2021版）[J].中华医学杂志，2021，101（16）：1132-1142.
[13] 石远凯.埃克替尼治疗非小细胞肺癌中国专家共识（2021年版）[J].中国新药杂志，2021，30（9）：803-808.
[14] 周彩存，王洁，王宝成，等.中国非小细胞肺癌免疫检查点抑制剂治疗专家共识（2020年版）[J].中国肺癌杂志，2021，24（4）：217-235.
[15] Yang S，Huang Y，Zhao Q. Epigenetic Alterations and Inflammation as Emerging Use for the Advancement of Treatment in Non-Small Cell Lung Cancer [J]. Front Immunol，2022，20（13）：878740.
[16] 易楠，金丹丹，纪易斐，等.基因芯片法检测血清中多组miRNAs对胰腺癌的诊断价值[J].中国临床研究，2022， 35（11）：1498-1502.
[17] 唐乐，李宏，何丽丽，等.MALAT1调控miR-19b-3p/HIF- 1α分子轴参与非小细胞肺癌的发生发展[J].华中科技大学学报（医学版），2022，51（5）：601-606.
[18] Chen F，Sun F，Liu X，et al. Glaucocalyxin A Inhibits the Malignant Progression of Epithelial Ovarian Cancer by Affecting the MicroRNA-374b-5p/HMGB3/Wnt-β-Catenin Pathway Axis [J]. Front Oncol，2022，14（12）：955830.
[19] Yi B，Li H，Cai H，et al. LOXL1-AS1 communicating with TIAR modulates vasculogenic mimicry in glioma via regulation of the miR-374b-5p/MMP14 axis [J]. J Cell Mol Med，2022，26（2）：475-490.
[20] Xu Q，Shi J，Zhang L，et al. Circ_0006006 facilitates non- small cell lung cancer progression by modulating miR-924/ SRSF7 axis [J]. J Gene Med，2022，24（5）：e341.
[21] Song J，Su ZZ，Shen QM. Long non-coding RNA MALAT1 regulates proliferation，apoptosis，migration and invasion via miR-374b-5p/SRSF7 axis in non-small cell lung cancer [J]. Eur Rev Med Pharmacol Sci，2020，24（4）：1853-1862.
[22] 姜婧琦，宋雨童，卢育彤，等.抗血管生成靶向药物在肿瘤治疗中的研究进展[J].山东医药，2022，62（22）：86-90.
[23] 黄崇青，黄景勇，裘益辉.VEGF-A和VEGF-C双拮抗抑制血管瘤内皮细胞增殖的实验研究[J].浙江医学，2021，43（4）：364-367，372.
[24] Huang B，Lu Y，Gui M，et al. Qingjie Fuzheng Granule suppresses lymphangiogenesis in colorectal cancer via the VEGF-C/VEGFR-3 dependent PI3K/AKT pathway [J]. Biomed Pharmacother，2021，6（137）：111331.
[25] 甘云辉，李应军，李凤霞，等.斑蝥酸钠维生素B6注射液联合SOX方案对晚期胃癌患者miR-18a、miR-34a及免疫细胞计数的影响[J].现代消化及介入诊疗，2021， 26（12）：1551-1555.
[26] Zhou H，Geng F，Chen Y，et al. The mineral dust-induced gene，mdig，regulates angiogenesis and lymphangiogenesis in lung adenocarcinoma by modulating the expression of VEGF-A/C/D via EGFR and HIF-1α signaling [J]. Oncol Rep，2021，45（5）：60.
[27] 赵丽霞，任成波，翟明慧，等.miR-374b-5p靶向VEGFC对肺癌细胞迁移、侵袭及上皮-间质转化的影响[J].中国老年学杂志，2022，42（22）：5593-5598.
京公网安备 11010502046598号